EGFR and melanoma: The pathway analysis identified eight significantly altered pathways with p-values of <0.0005 (Table 2), namely the VEGFA-VEGFR2 signaling pathway (WP:3888), endoderm differentiation (WP:2853), the brain-derived neurotrophic factor (BDNF) signaling pathway (WP:2380), insulin signaling (WP:481), the mesodermal commitment pathway (WP:2857), ErbB signaling (WP:673), melanoma (WP:4685) and hematopoietic stem cell gene regulation by the GABP alpha/beta complex (WP:3657).